Delivery Order SPE2DB20D3111-SPE2DB25FA8YR
- Not listed
- The Defense Logistics Agency awarded a $1,525.20 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Zepbound 7.5 mg/0.5 mL pen injectors on September 3, 2025, with completion expected by September 4, 2025. This non-set-aside contract represents a single delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.999 billion global pharmaceutical support vehicle running through December 2026. The order will be...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 25, 2025, for the supply of Zepbound 5 mg/0.5 ml pen injectors with a ceiling value of $3,812.90. This is a firm fixed-price delivery order with an ultimate completion date of July 28, 2025, and will be performed at AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania. The contract was competitively awarded with no set-aside designation. This delivery order is issued under...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $12,118.02 to AmerisourceBergen Drug Corp for the supply of Zepbound 10 mg/0.5 ml pen injectors on June 9, 2025, with an ultimate completion date of June 10, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a $3,544.47 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Zepbound 2.5 mg/0.5 mL pen injectors on July 31, 2025, with an ultimate completion date of August 1, 2025. This non-set-aside delivery order is being performed at the contractor's corporate office location in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, fulfills this order as a child contract under...
- The Defense Logistics Agency awarded a $5,918.72 firm fixed price delivery order to AmerisourceBergen Drug Corp for Zepbound 10 mg/0.5 ml pen injections on June 2, 2025, with an ultimate completion date of June 3, 2025. This competitive, non-set-aside award was issued from AmerisourceBergen's Conshohocken, Pennsylvania location and represents a single delivery order under the company's larger contract vehicle with DLA. Zepbound (tirzepatide) is a GLP-1 receptor agonist used for weight management...
- The Defense Logistics Agency awarded a $15,525.98 delivery order to AmerisourceBergen Drug Corp for Zepbound 5 mg/0.5 mL pen injections on August 4, 2025, with completion targeted for August 5, 2025. This firm fixed-price delivery order was competitively awarded without set-aside restrictions and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Zepbound (tirzepatide) is a GLP-1 receptor agonist indicated for weight management, reflecting the...
- The Defense Logistics Agency awarded a delivery order valued at $26,657.11 to AmerisourceBergen Drug Corp for the supply of Zepbound 2.5 mg/0.5 mL pen injections on August 20, 2025, with an ultimate completion date of August 21, 2025. This competitively awarded, non-set-aside firm fixed price delivery order is being performed at the contractor's facility in Conshohocken, Pennsylvania. Zepbound (tirzepatide) is a diabetes and weight management medication, consistent with AmerisourceBergen's...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $7,621.24 for Zepbound 5 mg/0.5 mL pens on August 4, 2025, with completion scheduled for August 5, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at the company's corporate office location in Conshohocken, Pennsylvania. Zepbound (tirzepatide) is a GLP-1 receptor agonist indicated for weight management, representing the...
- The U.S. Defense Logistics Agency's Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on August 15, 2025, for the supply of Zepbound 7.5 mg/0.5 mL pen injections with a ceiling value of $2,669.03. This is a firm fixed-price delivery order with an ultimate completion date of August 18, 2025. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, serves as a critical federal vendor for military and veteran...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 27, 2025, for the supply of Zepbound 5 mg/0.5 mL pen injectors, with a ceiling value of $10,513.23. This firm fixed-price delivery order, with an ultimate completion date of August 28, 2025, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999 through December 2026. The award was made without a...
- SPE2DB20D3111Indefinite Delivery Contract
- SPE2DB20D3111-SPE2DB25FA8YRDelivery Order
The Defense Logistics Agency awarded a $1,906.45 delivery order to AmerisourceBergen Drug Corp for Zepbound 10 mg/0.5 mL pen injectors on August 18, 2025. This non-competitive delivery order represents a firm fixed price transaction with a performance completion date of August 19, 2025. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This award is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999,999,999.00 comprehensive pharmaceutical supply vehicle valued through December 2026. Zepbound (tirzepatide) is a GLP-1 receptor agonist prescribed for weight management and diabetes treatment. This delivery order represents routine pharmaceutical procurement to support military healthcare operations and veteran medical services through the DLA's Medical Supply Chain. AmerisourceBergen's role as a prime pharmaceutical vendor enables it to supply a broad spectrum of medications and medical commodities to the Defense Health Agency, U.S. Coast Guard, and other federal healthcare systems. The DLA is developing next-generation Pharmaceutical Prime Vendor Global Program contracts planned for multiple regional awards, positioning AmerisourceBergen alongside other qualified contractors to maintain comprehensive pharmaceutical support for military and federal health programs worldwide.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.9k | 8/18/25 |